Cargando…
Anti-connective tissue growth factor (CTGF/CCN2) monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosis
BACKGROUND: Systemic sclerosis (SSc) is characterized by fibrosis of the skin and internal organs. Although the involvement of connective tissue growth factor (CTGF/CCN2) has been well-documented in SSc fibrosis, the therapeutic potential of targeting CTGF in SSc has not been fully investigated. Our...
Autores principales: | Makino, Katsunari, Makino, Tomoko, Stawski, Lukasz, Lipson, Kenneth E., Leask, Andrew, Trojanowska, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470189/ https://www.ncbi.nlm.nih.gov/pubmed/28610597 http://dx.doi.org/10.1186/s13075-017-1356-3 |
Ejemplares similares
-
Driving fibrosis in neuromuscular diseases: Role and regulation of Connective tissue growth factor (CCN2/CTGF)
por: Rebolledo, Daniela L., et al.
Publicado: (2021) -
Neuronal CTGF/CCN2 negatively regulates myelination in a mouse model of tuberous sclerosis complex
por: Ercan, Ebru, et al.
Publicado: (2017) -
Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease?
por: Leask, Andrew, et al.
Publicado: (2009) -
Connective tissue growth factor (CCN2, CTGF) and organ fibrosis: lessons from transgenic animals
por: Brigstock, David R.
Publicado: (2009) -
Myocardial Connective Tissue Growth Factor (CCN2/CTGF) Attenuates Left Ventricular Remodeling after Myocardial Infarction
por: Gravning, Jørgen, et al.
Publicado: (2012)